Addendum: Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment

Gennady M. Zharinov; Oleg A. Bogomolov; Irina V. Chepurnaya; Natalia Yu. Neklasova; Vladimir N. Anisimov

doi:10.18632/oncotarget.28363

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment

PDF | How to cite

Oncotarget. 2023; 14:149-149. https://doi.org/10.18632/oncotarget.28363

Metrics: PDF 805 views | ?

Gennady M. Zharinov¹, Oleg A. Bogomolov¹, Irina V. Chepurnaya¹, Natalia Yu. Neklasova¹ and Vladimir N. Anisimov²

¹A.M. Granov Russian Research Center for Radiology and Surgical Technologies of the Ministry of Health of the Russian Federation, Pesochny, St. Petersburg 197758, Russia
²N.N. Petrov National Medical Research Center of Oncology, Pesochny, St. Petersburg 197758, Russia

Published: February 25, 2023

Copyright: © 2023 Zharinov et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Patient consent was required and obtained. This study was approved by the Russian Research Centre of Radiology and Surgical Technologies Ethics Committee (Approval #1041Y).

Original article: Oncotarget. 2020; 11:3723–3729. DOI: https://doi.org/10.18632/oncotarget.27757

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28363

Publication Alerts

Post-Publication Promotion

Publication Discount

Addendum:

Addendum: Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment